← Back to Portfolio

Tizona Therapeutics

Tizona Therapeutics is a US immunotherapy company developing a pipeline of novel antibody therapeutics with potential in a broad range of cancers and autoimmune diseases. Tizona’s lead candidate is expected to start clinical trials in 2017 for cancer.  President and CEO Pablo Cagnoni, formerly President of Onyx Pharmaceuticals, a subsidiary of Amgen, leads the experienced management team.

Location South San Francisco, California
CEO Pablo Cagnoni
Partner Shelley Chu
Website www.tizonatx.com